WaveMan
WaveMan · Company
SGMT · Sagimet Biosciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SGMT Sagimet Biosciences (SGMT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001400118
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
96
13F, latest reported quarter
Conversions, 180 days
4
Codes C/M, not in net · $2.4M priced

What the filings say about SGMT

Insiders, 180 days
-$4.5M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.5M
2 notices

Sagimet Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Sagimet Biosciences Inc. insiders sold a net $4.5M of stock across 23 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kemble George
Director
SELL
2026-08-17 SECtraded 2026-08-14
350,987
$3.6M
-9.6%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 11, 2026.
  • The trade is 564.6% of the 62,161 shares held after it.
  • 2 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kemble George sold about $3.6M of SGMT on Aug 14, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Kemble George
Director
SELL
2026-08-12 SECtraded 2026-08-11
20,206
$201.1K
+3.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jul 20, 2026.
  • The trade is 32.5% of the 62,161 shares held after it.
  • 2 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kemble George sold about $201.1K of SGMT on Aug 11, 2026; 2 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Happel David
President & CEO
SELL
2026-07-22 SECtraded 2026-07-20
64,051
$497.1K
+36.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on Feb 10, 2026.
  • +65.1% median (+97.5% mean) 90-day return after 3 previous buys.
  • The trade is 8.6% of the 741,570 shares held after it.
  • 2 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Happel David sold about $497.1K of SGMT on Jul 20, 2026; 2 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Kemble George
Director
SELL
2026-07-22 SECtraded 2026-07-20
18,844
$140.5K
+36.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 20, 2025.
  • The trade is 30.3% of the 62,161 shares held after it.
  • 2 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kemble George sold about $140.5K of SGMT on Jul 20, 2026; 2 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
Rozek Elizabeth
Chief Legal & Admin. Officer
SELL
2026-07-22 SECtraded 2026-07-20
10,545
$81.8K
+36.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Feb 10, 2026.
  • The trade is 4.7% of the 224,414 shares held after it.
  • 2 other insiders sold within 30 days.
  • 96 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Admin. Officer Rozek Elizabeth sold about $81.8K of SGMT on Jul 20, 2026; 2 other insiders sold within 30 days and 96 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$4.5M over 180 days
-$3.8M over 90 days
below 78% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
96 funds bought in last quarter
more than 66% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-2551.9% net margin
below 93% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
20.4% of the float short (float per yahoo 2026-10-27) · 8.2 days to cover · settled 2026-10-15
the highest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SGMT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+30.4%12M
-38%-8%+22%+52%2025-102025-122026-022026-042026-062026-082026-10 2026-08-14 · Kemble George sold $3.6M2026-07-20 · Happel David sold $497.1K2025-11-20 · Kemble George sold $289.8K2026-08-11 · Kemble George sold $201.1K2026-07-20 · Kemble George sold $140.5K2026-07-20 · Rozek Elizabeth sold $81.8K2026-02-10 · Happel David sold $64.9K2026-02-10 · Martins Eduardo Bruno sold $19.5K2026-02-10 · Rozek Elizabeth sold $14.1K2026-02-10 · Chauche Thierry sold $7.0K2026-08-14 · GEORGE KEMBLE filed to sell $3.3M2026-08-11 · GEORGE KEMBLE filed to sell $193.4K2026-07-20 · GEORGE KEMBLE filed to sell $147.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SGMT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
6,575,788 sh
$50.8M
Balyasny Asset Management L.P.
3,626,113 sh
$28.0M
Woodline Partners LP
3,000,652 sh
$23.2M
SILVERARC CAPITAL MANAGEMENT, LLC
2,927,698 sh
$22.6M
VANGUARD CAPITAL MANAGEMENT LLC
2,566,272 sh
$19.8M

Congress trades in SGMT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SGMT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
GEORGE KEMBLE
Filed 2026-08-14
$3.3M
GEORGE KEMBLE
Filed 2026-08-11
$193.4K
GEORGE KEMBLE
Filed 2026-07-20
$147.4K

SGMT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$1.3M position · as of 2026-06-30
1.3%
Federated Hermes Kaufmann Small Cap Fund
$14.8M position · as of 2026-07-31
0.5%
Ultra-Small Company Market Fund
$378.0K position · as of 2026-06-30
0.3%
iShares Health Innovation Active ETF
$12.0K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$1.5M position · as of 2026-06-30
0.1%
BlackRock Health Sciences Opportunities Portfolio
$4.3M position · as of 2026-05-29
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
8 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
2
Phase 2
0 active
3
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.5M sold by insiders over 180 days, 96 funds added last quarter, $3.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SGMT financials

Net margin
-2551.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-24.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-23.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-27.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/an/a$2.0Mn/a
Operating income-$56.9M-$54.5M-$30.7M-$31.1M
Net income-$51.0M-$45.6M-$27.9M-$30.5M
EPS (diluted)-1.58-1.45-2.66-165.20
Operating cash flow-$45.6M-$42.4M-$23.8M-$24.5M
Cash$35.0M$75.8M$75.1M$158.0K
SEC XBRL, fiscal years, as known on 2026-10-28

SGMT Stock Sonar score 4/7 axes

Find similar shapesCompare

SGMT ranks highest on profitability (68th percentile) and institutional and government (66th), and lowest on insider conviction (10th), among Pharma & Biotech peers.

Profitability
68
Inputs
  • Return on equity-24.4% · 70 pct, sector of 545
  • Return on assets-23.5% · 65 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-27.1% · 69 pct, sector of 576
Insider conviction
10
Inputs
  • Net Form 4 buying (codes P and S), 180d-$4.5M · 19 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
66
Inputs
  • Funds adding, latest quarter96 · 66 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
47
Inputs
  • Short interest, % of float+20.4% · 14 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.7% · 80 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SGMT filings, in plain words

Are Sagimet Biosciences insiders buying or selling SGMT?

In the 180 days to 2026-10-28, Sagimet Biosciences insiders were net sellers, a net $4.5M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of SGMT?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $3.5M of stock; the latest, by GEORGE KEMBLE, was filed 2026-08-14.

Read the full summary

In the 180 days to 2026-10-28, Sagimet Biosciences insiders were net sellers of SGMT, a net $4.5M across purchases and sales reported on Form 4 by 3 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $3.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies